NEW YORK CITY, NY / ACCESS Newswire / November 17, 2026 / On November 12, 2026, Cellebrite DI Ltd. (NASDAQ: CLBT) furnished a Form 6-K to the U.S. Securities and Exchange Commission that lowered its full-year revenue guidance again, and CLBT shares were down approximately 14% that same day. If you bought Cellebrite stock before that filing and are now holding a loss, you may have legal rights. Investors who lost money are encouraged to submit your CLBT loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
As a foreign private issuer, Cellebrite reports its quarterly results to the SEC on Form 6-K. The November 12 filing reported third-quarter revenue of $149.0 million. It set fourth-quarter revenue guidance at $145 million to $150 million and left full-year annual recurring revenue (ARR) guidance unchanged. The revenue revision followed an earlier guidance cut that Cellebrite announced in August 2026.
CLBT traded higher early in the session after the results were released. Later in the day, shares were down approximately 14%. Levi & Korsinsky is investigating potential securities law violations, including whether Cellebrite's SEC filings and public statements about its revenue outlook met federal disclosure requirements.
If you purchased Cellebrite shares and suffered a loss, request a confidential review of your losses or call (212) 363-7500.
WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered billions of dollars for investors.
Frequently Asked Questions About the CLBT Investigation
Q: Who is eligible to participate in the CLBT investigation? A: Investors who purchased CLBT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did CLBT stock drop? A: Shares fell approximately 14% on November 12, 2026. The decline came after the Company furnished third-quarter results to the SEC that included another reduction to its full-year revenue guidance. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Cellebrite DI made false or misleading statements about its revenue outlook and full-year guidance. When the Company disclosed another reduction to its full-year revenue guidance on November 12, 2026, the stock price declined sharply.
Q: What do CLBT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my CLBT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CLBT and sold at a loss may still participate in the investigation.
Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire